Drug Profile
Research programme: diagnostic and imaging agents - GE Healthcare/NCI
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator GE Healthcare; National Cancer Institute (USA)
- Class Imaging agents
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Cardiovascular disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer(Diagnosis) in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders(Diagnosis) in USA
- 23 Sep 2008 Preclinical trials in Cardiovascular disorders (diagnosis) in USA (unspecified route)